Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Dishman Carbogen Amcis
Small Cap•1,132 Employees•IPO 2017
Current Price
₹164.56
0.55 (0.34%)Updated
Today's Range
₹161.59
₹167.57
₹164.56
52 Week Range
52W Low₹162.72
52W High₹321.95
₹164.56
Downside1.13%
Upside95.64%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹3,074.52 Cr
Market Cap
Total market value of companyP/E Ratio
25.88
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
0.68
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹7.57
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
1.78%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
2.42%
ROCE
Return on Capital Employed. >15% is goodNet Margin
4.25%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-53.82%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
5.82%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
35.20%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
134.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.41
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹371.95
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
59.30%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Dishman Carbogen Amcis Ltd boasts a strong promoter holding of 59.3%, signifying high confidence in the company's future and aligning management and shareholder interests. This stability is a significant positive for investors.
- •The company demonstrates a healthy operating profit margin (OPM) of 20.00%, showcasing efficient cost management and robust profit generation from core operations. This is a key indicator of financial health and profitability.
Weaknesses
5 points- •The company's Return on Equity (ROE) is a negative -0.32%, indicating insufficient returns on shareholder investments. This requires close monitoring and analysis of the underlying business performance to ensure improvement.
- •Dishman Carbogen Amcis Ltd has a substantial debt of 2389, resulting in a debt-to-equity ratio of 0.41. While not critically high, this level of debt could pose risks during economic downturns or profitability reductions.
Opportunities
3 points- •Foreign Institutional Investor (FII) holding has shown an upward trend, increasing from 5.85% in June 2022 to 8.07% in September 2025, indicating growing international investor interest.
- •Operating within the robust Pharmaceuticals and Healthcare sector, the company stands to benefit from increasing global demand, an aging population, and continuous innovation in drug development.
Threats
4 points- •The company faces intense competition from well-established industry giants like Sun Pharma and Divi's Lab, which possess significantly larger market shares and superior financial metrics.
- •The stock exhibits notable price volatility, with a 52-week range from 177.00 to 322.00, exposing investors to potential capital erosion during market downturns or adverse news.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹179.52 | +₹14.96 | +9.09% |
| R3 | ₹173.54 | +₹8.98 | +5.45% |
| R2 | ₹170.55 | +₹5.99 | +3.64% |
| R1 | ₹167.56 | +₹3.00 | +1.82% |
| PIVOT | ₹164.57 | 0.01 | 0.01% |
| CURRENT | ₹164.56 | - | - |
| S1 | ₹149.62 | -₹14.94 | -9.08% |
| S2 | ₹155.60 | -₹8.96 | -5.45% |
| S3 | ₹158.59 | -₹5.97 | -3.63% |
| S4 | ₹161.58 | -₹2.98 | -1.81% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+10.8% vs avg
3.61L
(04 Mar 2026)Delivery %+8.1% vs avg
58.4%
(04 Mar 2026)Avg Volume (20D)20-day average
3.25L
(04 Feb - 04 Mar)Avg Delivery %Trend ↑
50.3%
(04 Feb - 04 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Sai Life Sciences Ltd
548.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %
Peer Comparison
| Company Name |
|---|
 Akums Drugs & Pharmaceuticals Ltd |
 Borosil Scientific Ltd |
 Brooks Laboratories Ltd |
 Divis Laboratories Ltd |
 |
 Indegene Ltd |
 Innova Captab Ltd |
 OneSource Specialty Pharma Ltd |
 Sai Life Sciences Ltd |
 Suven Life Sciences Ltd |
 Tarsons Products Ltd |
 Vimta Labs Ltd |
 Windlas Biotech Ltd |
About
Dishman Carbogen Amcis Ltd
Dishman Carbogen Amcis Limited (DCAL) is a global contract research and manufacturing services (CRAMS) provider catering to the pharmaceutical, healthcare, and biotechnology sectors. Their core business revolves around offering comprehensive services throughout the drug development and manufacturing lifecycle, from research and development to the production of finished products. This broad scope allows them to partner with clients across various stages of drug development and commercialization.
The company's operations are primarily structured around two segments: Contract Research and Manufacturing Services and Marketable Molecules. The CRAMS segment focuses on providing customized solutions for clients' research and manufacturing needs, encompassing a wide range of services tailored to specific client requirements. This includes everything from the initial stages of drug discovery and development to large-scale manufacturing of pharmaceutical products.
The Marketable Molecules segment involves the manufacturing and supply of various pharmaceutical and related products. This segment includes a diverse portfolio of offerings, ranging from bulk drugs and active pharmaceutical ingredients (APIs), including both general and highly potent APIs, to specialty chemicals used in pharmaceutical and cosmetic applications. Specific examples of their manufactured products include intermediates, fine chemicals, phosphoranes, solid quaternary ammonium compounds, and Wittig reagents.
Beyond these core offerings, DCAL also produces a range of other products. This diversification further strengthens their market position and demonstrates their commitment to providing a wide array of solutions to their clients. Their product portfolio extends to vitamin D products and analogues, personal care items like hand and body wash, sanitizers, and antiseptics, and even phase transfer catalysts, soft gel capsules, disinfectant formulations, cholesterol-related products, lanolin-related products, and liquid and lyophilized sterile injectables.
Established in 1983 and headquartered in Ahmedabad, India, DCAL is a subsidiary of Adimans Technologies LLP. Their extensive product range and comprehensive service offerings position them as a significant player in the global pharmaceutical and healthcare industries, providing a valuable link in the chain from drug discovery to market delivery.
COMPANY FACTS - DCAL
Registered Address
Dishman Corporate House, Iscon-Bopal Road, Ambli
Ahmedabad
GUJARAT
IN
Tel: 912717420100
Website:https://www.carbogen-amcis.com/
Investor Relations:http://imdcal.com/investor-relations
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Life Sciences Tools & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,132
IPO Date: 21/09/2017
MANAGEMENT - DCAL
Mr. Harshil Dalal
Global Chief Financial Officer
Ms. Shrima Dave
Compliance Officer, Company Secretary
Mr. Arpit Vyas
Global Managing Director, Executive Director
Mrs. Deohooti Vyas
Whole-Time Director
Mr. Dhaval Shah
Non-Executive Non-Independent Director
Mr. Kulin Shah
Independent Director
Mr. Hemantkumar Jayantiprasad Bhatt
Non-Executive Independent Director
Ms. Margie Parikh
Non-Executive Independent Director
Investor Questions Answered
Dishman Carbogen Amcis Ltd (DCAL) Stock FAQs
Get answers to the most common questions about Dishman Carbogen Amcis Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Dishman Carbogen Amcis Ltd (DCAL) is ₹164.56. Today, the stock has gained by ₹0.55 (0.34%), trading in a range of ₹161.59 to ₹167.57. The stock opened at ₹165 with a trading volume of 4,08,013 shares.
Dishman Carbogen Amcis Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹3,074.52 crores, P/E ratio of 25.88, ROE of 1.78%, and ROCE of 2.42%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Dishman Carbogen Amcis Ltd (DCAL) is ₹321.95, while the 52-week low is ₹162.72. Currently trading at ₹164.56, the stock is 1.2% away from its 52-week low and 48.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Dishman Carbogen Amcis Ltd stock at ₹164.56 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.88 and P/B ratio of N/A. Today's performance shows a gain of 0.34%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Dishman Carbogen Amcis Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹164.56, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Dishman Carbogen Amcis Ltd's key financial metrics include: P/E Ratio: 25.88, P/B Ratio: N/A, ROE: 1.78%, ROCE: 2.42%, Dividend Yield: 0.00%, EPS: ₹7.57, Book Value: ₹371.95, Debt-to-Equity: 0.41, and Current Ratio: N/A. The company's market cap stands at ₹3,074.52 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Dishman Carbogen Amcis Ltd stock opened at ₹165 and is currently trading at ₹164.56, showing a gain of ₹0.55 (0.34%). The intraday high is ₹167.57 and low is ₹161.59. The trading volume stands at 4,08,013 shares, indicating moderate market participation today.
Dishman Carbogen Amcis Ltd has a Price-to-Earnings (P/E) ratio of 25.88, which means investors are willing to pay ₹25.88 for every ₹1 of earnings. With an EPS of ₹7.57, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Dishman Carbogen Amcis Ltd has a market capitalization of ₹3,074.52 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹164.56) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Dishman Carbogen Amcis Ltd has a book value of ₹371.95 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹164.56, which is 55.8% below the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Dishman Carbogen Amcis Ltd has a Return on Equity (ROE) of 1.78% and Return on Capital Employed (ROCE) of 2.42%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Dishman Carbogen Amcis Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Dishman Carbogen Amcis Ltd has a debt-to-equity ratio of 0.41, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Dishman Carbogen Amcis Ltd has an Earnings Per Share (EPS) of ₹7.57, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹164.56 and P/E ratio of 25.88, investors are paying 25.88 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Dishman Carbogen Amcis Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Dishman Carbogen Amcis Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Dishman Carbogen Amcis Ltd stock, consider: 1) Fundamental Analysis - Review P/E (25.88), ROE (1.78%), debt-to-equity (0.41), and growth rates. 2) Technical Analysis - Check 52-week range (₹162.72 - ₹321.95), moving averages, and chart patterns. 3) Valuation - Compare current price (₹164.56) with book value (₹371.95) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Dishman Carbogen Amcis Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹164.56 is 8128x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Dishman Carbogen Amcis Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹162.72 - ₹321.95). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.41 indicates leverage. 4) Liquidity Risk - Based on trading volume of 4,08,013 shares. 5) Valuation Risk - P/E of 25.88 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Dishman Carbogen Amcis Ltd operates in the industry with key metrics: P/E ratio of 25.88, ROE of 1.78%, market cap of ₹3,074.52 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.41), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Dishman Carbogen Amcis Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹164.56, with a 52-week range of ₹162.72 to ₹321.95. Based on fundamentals like P/E (25.88), ROE (1.78%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Dishman Carbogen Amcis Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹164.56. 2) Fundamental Deterioration - Declining ROE (currently 1.78%), increasing debt (D/E: 0.41), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Dishman Carbogen Amcis Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu